- Molecular NameOseltamivir
- SynonymOseltamivir phosphate
- Weight312.41
- Drugbank_IDDB00198
- ACS_NO196618-13-0
- Show 2D model
- LogP (experiment)1.115
- LogP (predicted, AB/LogP v2.0)1.22
- pkaN/A
- LogD (pH=7, predicted)-0.16
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)-0.65
- LogSw (predicted, AB/LogsW2.0)1.49
- Sw (mg/ml) (predicted, ACD/Labs)4.81
- No.of HBond Donors3
- No.of HBond Acceptors6
- No.of Rotatable Bonds8
- TPSA90.65
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antiviral drug that slows the spread of influenza (flu) virus between cells in the body by stopping the virus from chemically cutting ties with its host cell
- Absorption_value75.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability75.0
- Protein binding42.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic, to GS4071; Extensively converted to oseltamivir carboxylate by esterases located predominantly in the liver. Neither oseltamivir nor oseltamivir carboxylate is a substrate for, or inhibitor of, cytochrome P450 isoforms. At least 75% of an oral dose reaches the systemic circulation as oseltamivir carboxylate.
- Half life1~3 h
- ExcretionRenal (GS4071)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityAt present, there has been no experience with overdose. Single doses of up to 1000 mg of oseltamivir have been associated with nausea and/or vomiting.
- LD50 (rat)N/A
- LD50 (mouse)LD50=100 mg/kg (intravenous)